Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −51.5%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.07 0.50 −0.74%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 44.8×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Royalty Pharma PLC 10-K filed Feb 12, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 12, 2025 · accepted 9:20 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov